Company Analysis
Sign in

Kiniksa Pharmaceuticals International, plc (KNSA)

Nasdaq: KNSA · Pharmaceutical Preparations · London · filing with the SEC since 2018
Full chart Alerts Compare
Grade7.2
◀ Past 7.8● Present 7.7▶ Future 5.7
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

4 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Kiniksa Pharmaceuticals International, plc’s names, not what it holds today.

Patents granted
4
4 utility, 1976 to Dec 31, 2025
Granted in 2025
none
in the last year the record reads
Applications published
5
since 2001, to Dec 31, 2025
Names they are printed under
2
a subsidiary
By yearGrantedApplications published
'18'19'20'22
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Primatope Therapeutics Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
5 published
Primatope Therapeutics Inc. a subsidiary
US, as the owner printed on each patent
4 granted
0 published
Names not counted (2)
Kiniksa Pharmaceuticals, Ltd.
Most of its patents print BM; this name counts in GB, US. 0 granted and 27 published under it are not counted.
Kiniksa Pharmaceuticals, Ltd.
Most of its patents print BM; this name counts in GB, US. 10 granted and 2 published under it are not counted.
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Sep 13, 202211,439,706Polynucleotides encoding a humanized anti-CD40 antibodyPharmaceuticalsPrimatope Therapeutics Inc.
Sep 15, 202010,772,958Humanized anti-CD40 antibodies and methods of administering thereofPharmaceuticalsPrimatope Therapeutics Inc.
Feb 12, 201910,201,608Polynucleotides encoding humanized anti-CD40 antibodiesPharmaceuticalsPrimatope Therapeutics Inc.
May 22, 20189,974,855Humanized anti-CD40 antibodies and methods of administering thereofPharmaceuticalsPrimatope Therapeutics Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Dec 8, 20222022/0387587HUMANIZED ANTI-CD40 ANTIBODIES AND USES THEREOFPharmaceuticalsPrimatope Therapeutics Inc.
Dec 10, 20202020/0384107HUMANIZED ANTI-CD40 ANTIBODIES AND USES THEREOFPharmaceuticalsPrimatope Therapeutics Inc. · patent 11,439,706 granted from it
Apr 25, 20192019/0117771HUMANIZED ANTI-CD40 ANTIBODIES AND METHODS OF ADMINISTERING THEREOFPharmaceuticalsPrimatope Therapeutics Inc. · patent 10,772,958 granted from it
Oct 4, 20182018/0280507HUMANIZED ANTI-CD40 ANTIBODIES AND USES THEREOFPharmaceuticalsPrimatope Therapeutics Inc. · patent 10,201,608 granted from it
Mar 22, 20182018/0078640HUMANIZED ANTI-CD40 ANTIBODIES AND USES THEREOFPharmaceuticalsPrimatope Therapeutics Inc. · patent 9,974,855 granted from it

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton KNSA · research, not advice